# Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma

> **NCT02423837** · PHASE3 · UNKNOWN · sponsor: **National Research Center for Hematology, Russia** · enrollment: 200 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Rituximab, bendamustine

## Key facts

- **NCT ID:** NCT02423837
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2016-02
- **Final completion:** 2021-04
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2015-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423837, "Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02423837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*